BeiGene, Ltd. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Amounts below are U.S. dollars; financial statement amounts are generally in millions unless stated otherwise. The filing identifies the registrant as BeiGene, Ltd.
Business context and results
BeiGene is a global biotechnology company focused on oncology, with internally developed medicines including BRUKINSA (zanubrutinib), TEVIMBRA (tislelizumab) and pamiparib, alongside in-licensed products and a global clinical development and manufacturing program.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Total revenue | $781.3 | $387.6 | $1,824.4 | $1,035.8 |
| Net product revenue | $595.3 | $349.5 | $1,559.3 | $915.6 |
| Collaboration revenue | $186.0 | $38.1 | $265.0 | $120.2 |
| Operating loss | $(134.0) | $(438.4) | $(823.9) | $(1,321.0) |
| Net income (loss) | $215.4 | $(557.6) | $(514.2) | $(1,558.5) |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $(935.8) | $(1,178.4) |
Financial position and key changes
- Q3 revenue rose 101.6% year over year; product revenue increased 70.3%. BRUKINSA sales were $357.7 million, up 130.0%, and tislelizumab sales were $144.4 million, up 12.6%.
- Q3 product gross margin was 83.8%, compared with 78.1% a year earlier. Nine-month product gross margin was 82.4%, versus 76.7%.
- Q3 net income included a $362.9 million noncash gain from the BMS settlement. The nine-month net loss therefore remains a more representative indicator of ongoing losses than Q3 net income alone.
- At September 30, cash and cash equivalents were $3,067.3 million, short-term investments $107.0 million, and restricted cash $13.6 million. Cash, cash equivalents and restricted cash totaled $3,080.9 million, down $794.1 million from year-end 2022.
- Total debt was approximately $531.1 million, including $328.6 million current debt and $202.5 million long-term bank loans. The $150 million China Minsheng Bank senior loan was repaid in October 2023.
- Total assets were $5,524.9 million and shareholders’ equity was $3,763.2 million. Accumulated deficit was $7,594.5 million.
- Capital expenditures were $404.9 million for the first nine months. Property, plant and equipment included $631.1 million of construction in progress, of which $419.5 million related to the Hopewell, New Jersey facility.
Outlook, developments and risks
- Management said existing cash, cash equivalents and short-term investments were expected to fund operating expenses and capital requirements for at least 12 months after issuance of the financial statements. The company also cautioned that additional funding may be needed to complete all planned development, launches and investments. No specific revenue or earnings guidance is provided in the supplied filing text.
- Novartis and BeiGene mutually terminated their tislelizumab collaboration in September and their ociperlimab option and collaboration in July. BeiGene regained global rights to both programs; deferred collaboration revenue was recognized upon termination. Novartis may continue certain tislelizumab clinical trials under agreed terms.
- The BMS settlement ended the ABRAXANE arbitration and other disputes. BMS returned 23.3 million BeiGene ordinary shares, recorded as a $362.9 million noncash gain. REVLIMID and VIDAZA sales may continue from existing inventory until sold or December 31, 2024; the BMS license and quality agreements terminate December 31, 2023.
- Management cited BRUKINSA launch momentum, expanding commercialization and an intention to improve operating leverage while maintaining moderate expense growth. Research and development and selling, general and administrative expenses nevertheless increased year over year.
- Material risks include clinical-trial and regulatory uncertainty, pricing and reimbursement pressure, competition, manufacturing and supply dependence, foreign-exchange exposure, PRC regulatory and data-security uncertainty, and ongoing operating cash burn. RMB depreciation reduced reported cash by $50.3 million in the first nine months.
- Pharmacyclics alleges BRUKINSA infringes a U.S. patent and seeks unspecified damages and other relief. The suit was stayed pending BeiGene’s post-grant review petition, filed November 1, 2023. The filing states that BeiGene intends to defend the claims.
Important facts for investors to verify
- How much of Q3 collaboration revenue and reported net income reflects one-time recognition after the Novartis terminations and BMS settlement, versus recurring operations.
- Whether BRUKINSA sales growth and product gross margins can continue as reimbursement, pricing and competition evolve across markets.
- Cash burn, working-capital needs and planned capital spending, including the $442.6 million in capital commitments and $517.5 million remaining Amgen co-development commitment.
- Repayment and refinancing of debt maturities, including the October 2023 repayment of the $150 million senior loan.
- Progress and potential financial impact of the Pharmacyclics patent proceeding, regulatory reviews, and the company’s regained global development responsibilities for TEVIMBRA and ociperlimab.